Why Is Seagen Stock Trading Higher Today?
Portfolio Pulse from Vandana Singh
Seagen Inc and Astellas Pharma Inc released positive results from the KEYNOTE-A39 Phase 3 EV-302 trial for Padcev combined with Merck & Co Inc's Keytruda versus chemotherapy in bladder cancer. The trial met its dual primary endpoints of overall survival and progression-free survival compared to chemotherapy. The results are expected to confirm the current U.S. accelerated approval of Keytruda in combination with enfortumab vedotin as first-line treatment for urothelial carcinoma. Seagen's shares are up 3.54% at $213.69.
September 22, 2023 | 3:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Astellas Pharma Inc partnered with Seagen in the successful KEYNOTE-A39 Phase 3 EV-302 trial for bladder cancer.
Astellas Pharma Inc partnered with Seagen in the successful KEYNOTE-A39 Phase 3 EV-302 trial for bladder cancer. This positive result could potentially have a positive impact on Astellas Pharma's stock price.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Astellas Pharma Inc partnered with Seagen in the successful KEYNOTE-A39 Phase 3 EV-302 trial for bladder cancer.
Astellas Pharma Inc partnered with Seagen in the successful KEYNOTE-A39 Phase 3 EV-302 trial for bladder cancer. This positive result could potentially have a positive impact on Astellas Pharma's stock price.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Merck's Keytruda was used in combination with Seagen's Padcev in the successful KEYNOTE-A39 Phase 3 EV-302 trial for bladder cancer.
Merck's Keytruda was used in combination with Seagen's Padcev in the successful KEYNOTE-A39 Phase 3 EV-302 trial for bladder cancer. This positive result could potentially have a positive impact on Merck's stock price.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Seagen's stock is trading higher due to positive results from the KEYNOTE-A39 Phase 3 EV-302 trial for Padcev combined with Merck's Keytruda in bladder cancer.
Positive clinical trial results often lead to an increase in the stock price of the company involved. In this case, the successful results of the KEYNOTE-A39 Phase 3 EV-302 trial for Padcev combined with Merck's Keytruda in bladder cancer have led to a rise in Seagen's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100